{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:24:38Z","timestamp":1780568678771,"version":"3.54.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40257-022-00731-x","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T15:03:51Z","timestamp":1664377431000},"page":"69-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Advances in Topical Treatments of Cutaneous Malignancies"],"prefix":"10.1007","volume":"24","author":[{"given":"Yanci A.","family":"Algarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anokhi","family":"Jambusaria-Pahlajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-3478","authenticated-orcid":false,"given":"Vishal A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"issue":"3","key":"731_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.006","volume":"78","author":"JYS Kim","year":"2018","unstructured":"Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540\u201359. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.006.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"731_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","volume":"78","author":"JYS Kim","year":"2018","unstructured":"Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560\u201378. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.007.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"731_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.055.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"731_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1440-1681.1998.tb02339.x","volume":"25","author":"D Thomas","year":"1998","unstructured":"Thomas D, Zalcberg J. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998;25(11):887\u201395. https:\/\/doi.org\/10.1111\/j.1440-1681.1998.tb02339.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"731_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1524-4725.2007.33090.x","volume":"33","author":"K Gross","year":"2007","unstructured":"Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2007;33(4):433\u20139. https:\/\/doi.org\/10.1111\/j.1524-4725.2007.33090.x (discussion 440).","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg Al."},{"key":"731_CR6","unstructured":"Efudex-40TM (fluorouracil topical cream) prescribing information. Costa Mesa (CA): Valeant Pharmaceuticals International; 2004."},{"issue":"12","key":"731_CR7","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/archdermatol.2009.291","volume":"145","author":"WE Love","year":"2009","unstructured":"Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2009.291.","journal-title":"Arch Dermatol"},{"issue":"9","key":"731_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","volume":"151","author":"H Pomerantz","year":"2015","unstructured":"Pomerantz H, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015;151(9):952. https:\/\/doi.org\/10.1001\/jamadermatol.2015.0502.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"731_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","volume":"154","author":"MA Weinstock","year":"2018","unstructured":"Weinstock MA, Thwin SS, Siegel JA, Marcolivio K, Means AD, Leader NF, et al. Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial. JAMA Dermatol. 2018;154(2):167. https:\/\/doi.org\/10.1001\/jamadermatol.2017.3631.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"731_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380(10):935\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1811850.","journal-title":"N Engl J Med"},{"key":"731_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12822","author":"Y Wu","year":"2019","unstructured":"Wu Y, Tang N, Cai L, Li Q. Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis. Dermatol Ther. 2019. https:\/\/doi.org\/10.1111\/dth.12822.","journal-title":"Dermatol Ther"},{"issue":"2","key":"731_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/bjd.12343","volume":"169","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Paquet M. Network meta-analysis of the outcome \u2018participant complete clearance\u2019 in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169(2):250\u20139. https:\/\/doi.org\/10.1111\/bjd.12343.","journal-title":"Br J Dermatol"},{"issue":"10","key":"731_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/ijd.14106","volume":"57","author":"GT Prince","year":"2018","unstructured":"Prince GT, Cameron MC, Fathi R, Alkousakis T. Topical 5-fluorouracil in dermatologic disease. Int J Dermatol. 2018;57(10):1259\u201364. https:\/\/doi.org\/10.1111\/ijd.14106.","journal-title":"Int J Dermatol"},{"issue":"9","key":"731_CR14","first-page":"1","volume":"6","author":"AK Gupta","year":"2001","unstructured":"Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Ther Lett. 2001;6(9):1\u20134.","journal-title":"Skin Ther Lett."},{"issue":"3","key":"731_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1046\/j.1365-2133.2003.05033.x","volume":"148","author":"A Salim","year":"2003","unstructured":"Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized \ncomparison of photodynamic therapy with topical 5-fluorouracil in Bowen\u2019s disease. Br J Dermatol. 2003;148(3):539\u201343. https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05033.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"731_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archderm.142.6.729","volume":"142","author":"C Morton","year":"2006","unstructured":"Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol. 2006;142(6):729\u201335. https:\/\/doi.org\/10.1001\/archderm.142.6.729.","journal-title":"Arch Dermatol"},{"key":"731_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.08.045","author":"H Neale","year":"2021","unstructured":"Neale H, Michelon M, Jacob S, Pinkston M, Ukaegbu R, Zamor W, et al. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: a retrospective cohort analysis. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.045.","journal-title":"J Am Acad Dermatol"},{"key":"731_CR18","first-page":"549","volume":"7","author":"MS Litwin","year":"1972","unstructured":"Litwin MS, Ryan RF, Ichinose H, Reed RR, Kremetz ET. Proceedings: use of 5 fluorouracil in the topical therapy of skin cancer: a review of 157 patients. Proc Natl Cancer Conf. 1972;7:549\u201361.","journal-title":"Proc Natl Cancer Conf."},{"issue":"6","key":"731_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1067\/mjd.2001.113476","volume":"44","author":"B Hamouda","year":"2001","unstructured":"Hamouda B, Jamila Z, Najet R, Slim T, Rafiaa N, Noureddine B, et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol. 2001;44(6):1054. https:\/\/doi.org\/10.1067\/mjd.2001.113476.","journal-title":"J Am Acad Dermatol"},{"key":"731_CR20","unstructured":"FDA Approves Calcipotriene for Plaque Psoriasis in Adolescents. Medscape. Accessed October 12, 2021. http:\/\/www.medscape.com\/viewarticle\/913407"},{"issue":"6","key":"731_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125476","volume":"4","author":"AR Rosenberg","year":"2019","unstructured":"Rosenberg AR, Tabacchi M, Ngo KH, Wallendorf M, Rosman IS, Cornelius LA, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight. 2019;4(6): 125476. https:\/\/doi.org\/10.1172\/jci.insight.125476.","journal-title":"JCI Insight."},{"issue":"1","key":"731_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1172\/JCI89820","volume":"127","author":"TJ Cunningham","year":"2016","unstructured":"Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2016;127(1):106\u201316. https:\/\/doi.org\/10.1172\/JCI89820.","journal-title":"J Clin Invest"},{"issue":"5","key":"731_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1001\/jamadermatol.2018.4793","volume":"155","author":"GE Molina","year":"2019","unstructured":"Molina GE, Khalifian S, Mull JL, Chen L, Rosman IS, Faulkner-Jones BE, et al. Topical combination of fluorouracil and calcipotriene as a palliative therapy for refractory extramammary paget disease. JAMA Dermatol. 2019;155(5):599\u2013603. https:\/\/doi.org\/10.1001\/jamadermatol.2018.4793.","journal-title":"JAMA Dermatol"},{"issue":"1 Pt 2","key":"731_CR24","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1067\/mjd.2000.107808","volume":"43","author":"DN Sauder","year":"2000","unstructured":"Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1 Pt 2):S6-11. https:\/\/doi.org\/10.1067\/mjd.2000.107808.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"731_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1440-0960.2006.00265.x","volume":"47","author":"Y Vun","year":"2006","unstructured":"Vun Y, Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol. 2006;47(3):169\u201371. https:\/\/doi.org\/10.1111\/j.1440-0960.2006.00265.x.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"731_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.141.4.467","volume":"141","author":"N Korman","year":"2005","unstructured":"Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141(4):467\u201373. https:\/\/doi.org\/10.1001\/archderm.141.4.467.","journal-title":"Arch Dermatol"},{"issue":"9","key":"731_CR27","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archderm.138.9.1165","volume":"138","author":"S Shumack","year":"2002","unstructured":"Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165\u201371. https:\/\/doi.org\/10.1001\/archderm.138.9.1165.","journal-title":"Arch Dermatol"},{"issue":"5","key":"731_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","volume":"152","author":"HJ Schulze","year":"2005","unstructured":"Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferr\u00e1ndiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939\u201347. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06486.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"731_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s0190-9622(99)70261-6","volume":"41","author":"KR Beutner","year":"1999","unstructured":"Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41(6):1002\u20137. https:\/\/doi.org\/10.1016\/s0190-9622(99)70261-6.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"731_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/bjo.2010.193078","volume":"95","author":"E Garcia-Martin","year":"2011","unstructured":"Garcia-Martin E, Gil-Arribas LM, Idoipe M, Alfaro J, Pueyo V, Pablo LE, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol. 2011;95(10):1393\u20136. https:\/\/doi.org\/10.1136\/bjo.2010.193078.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"731_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","volume":"50","author":"J Geisse","year":"2004","unstructured":"Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722\u201333. https:\/\/doi.org\/10.1016\/j.jaad.2003.11.066.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"731_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/09546634.2019.1638883","volume":"31","author":"HX Jia","year":"2020","unstructured":"Jia HX, He YL. Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial. J Dermatol Treat. 2020;31(8):831\u20138. https:\/\/doi.org\/10.1080\/09546634.2019.1638883.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"731_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1067\/mjd.2002.126215","volume":"47","author":"JK Geisse","year":"2002","unstructured":"Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390\u20138. https:\/\/doi.org\/10.1067\/mjd.2002.126215.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"731_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1524-4725.2008.34378.x","volume":"35","author":"DF Butler","year":"2009","unstructured":"Butler DF, Parekh PK, Lenis A. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2009;35(1):24\u20139. https:\/\/doi.org\/10.1111\/j.1524-4725.2008.34378.x.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg Al."},{"issue":"6","key":"731_CR35","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1046\/j.1365-2133.2002.05069.x","volume":"147","author":"W Sterry","year":"2002","unstructured":"Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147(6):1227\u201336. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.05069.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"731_CR36","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaad.2007.05.022","volume":"57","author":"TK Eigentler","year":"2007","unstructured":"Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, M\u00f6hrle M, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2007.05.022.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"731_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1524-4725.2005.31081","volume":"31","author":"K Peris","year":"2005","unstructured":"Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2005;31(3):318\u201323. https:\/\/doi.org\/10.1111\/j.1524-4725.2005.31081.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg Al."},{"issue":"1","key":"731_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S1470-2045(13)70530-8","volume":"15","author":"F Bath-Hextall","year":"2014","unstructured":"Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PSJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96\u2013105. https:\/\/doi.org\/10.1016\/S1470-2045(13)70530-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"731_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jaad.2020.04.053","volume":"83","author":"KAE Sinx","year":"2020","unstructured":"Sinx KAE, Nelemans PJ, Kelleners-Smeets NWJ, Winnepenninckx VJL, Arits AHMM, Mosterd K. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial. J Am Acad Dermatol. 2020;83(2):469\u201376. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.053.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"731_CR40","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1684\/ejd.2012.1771","volume":"22","author":"D Tiodorovic-Zivkovic","year":"2012","unstructured":"Tiodorovic-Zivkovic D, Zalaudek I, Longo C, De Pace B, Albertini G, Argenziano G. Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients. Eur J Dermatol EJD. 2012;22(4):579\u201380. https:\/\/doi.org\/10.1684\/ejd.2012.1771.","journal-title":"Eur J Dermatol EJD."},{"issue":"4","key":"731_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1684\/ejd.2016.2788","volume":"26","author":"T Dirschka","year":"2016","unstructured":"Dirschka T, Schmitz L, Bartha \u00c1. Clinical and histological resolution of invasive squamous cell carcinoma by topical imiquimod 3.75%: a case report. Eur J Dermatol EJD. 2016;26(4):408\u20139. https:\/\/doi.org\/10.1684\/ejd.2016.2788.","journal-title":"Eur J Dermatol EJD."},{"issue":"6","key":"731_CR42","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2006.01.055","volume":"54","author":"GK Patel","year":"2006","unstructured":"Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen\u2019s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54(6):1025\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2006.01.055.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"731_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/LGT.0b013e31822d2484","volume":"16","author":"G Baiocchi","year":"2012","unstructured":"Baiocchi G, Begnami MDFS, Fukazawa EM, Surima WS, Badiglian-Filho L, Costa FD, et al. Conservative management of extramammary paget disease with imiquimod. J Low Genit Tract Dis. 2012;16(1):59\u201363. https:\/\/doi.org\/10.1097\/LGT.0b013e31822d2484.","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"731_CR44","first-page":"285","volume":"94","author":"EN Wilmer","year":"2014","unstructured":"Wilmer EN, Gustafson CJ, Ahn CS, Davis SA, Feldman SR, Huang WW. Most common dermatologic conditions encountered by dermatologists and nondermatologists. Cutis. 2014;94(6):285\u201392.","journal-title":"Cutis"},{"issue":"6","key":"731_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMoa2024040","volume":"384","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384(6):512\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2024040.","journal-title":"N Engl J Med"},{"issue":"11","key":"731_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","volume":"40","author":"JE Wolf","year":"2001","unstructured":"Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709\u201313. https:\/\/doi.org\/10.1046\/j.1365-4362.2001.01324.x.","journal-title":"Int J Dermatol"},{"issue":"1","key":"731_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","volume":"146","author":"JK Rivers","year":"2002","unstructured":"Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146(1):94\u2013100. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04561.x.","journal-title":"Br J Dermatol"},{"issue":"Suppl 3","key":"731_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.07856.x","volume":"156","author":"LF Fecker","year":"2007","unstructured":"Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156(Suppl 3):25\u201333. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07856.x.","journal-title":"Br J Dermatol"},{"issue":"12","key":"731_CR49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/nrd2154","volume":"5","author":"N Barker","year":"2006","unstructured":"Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5(12):997\u20131014. https:\/\/doi.org\/10.1038\/nrd2154.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"731_CR50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/sj.jid.5700191","volume":"126","author":"JW Tjiu","year":"2006","unstructured":"Tjiu JW, Liao YH, Lin SJ, Huang YL, Tsai WL, Chu CY, et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol. 2006;126(5):1143\u201351. https:\/\/doi.org\/10.1038\/sj.jid.5700191.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"731_CR51","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jaad.2016.01.050","volume":"75","author":"T Brinkhuizen","year":"2016","unstructured":"Brinkhuizen T, Frencken KJA, Nelemans PJ, Hoff MLS, Kelleners-Smeets NWJ, Zur Hausen A, et al. The effect of topical diclofenac 3% and calcitriol 3 \u03bcg\/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. J Am Acad Dermatol. 2016;75(1):126\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.050.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"731_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/ddg.14048","volume":"18","author":"MV Heppt","year":"2020","unstructured":"Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma\u2014short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2020;18(3):275\u201394. https:\/\/doi.org\/10.1111\/ddg.14048.","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG."},{"issue":"1","key":"731_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1468-3083.2011.04005.x","volume":"26","author":"A Pflugfelder","year":"2012","unstructured":"Pflugfelder A, Welter AK, Leiter U, Weide B, Held L, Eigentler TK, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol JEADV. 2012;26(1):48\u201353. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04005.x.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"1","key":"731_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1751-1097.1992.tb04222.x","volume":"55","author":"BW Henderson","year":"1992","unstructured":"Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55(1):145\u201357. https:\/\/doi.org\/10.1111\/j.1751-1097.1992.tb04222.x.","journal-title":"Photochem Photobiol"},{"issue":"2","key":"731_CR55","first-page":"44","volume":"2","author":"MH Gold","year":"2009","unstructured":"Gold MH. Therapeutic and Aesthetic Uses of Photodynamic Therapy Part five of a five-part series: ALA-PDT and MAL-PDT What Makes Them Different. J Clin Aesthetic Dermatol. 2009;2(2):44\u20137.","journal-title":"J Clin Aesthetic Dermatol."},{"issue":"1","key":"731_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaad.2006.06.006","volume":"56","author":"LR Braathen","year":"2007","unstructured":"Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125\u201343. https:\/\/doi.org\/10.1016\/j.jaad.2006.06.006.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"731_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/lsm.20470","volume":"39","author":"C Zane","year":"2007","unstructured":"Zane C, Capezzera R, Sala R, Venturini M, Calzavara-Pinton P. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med. 2007;39(3):203\u20139. https:\/\/doi.org\/10.1002\/lsm.20470.","journal-title":"Lasers Surg Med"},{"issue":"5","key":"731_CR58","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1365-2133.2005.07107.x","volume":"154","author":"SR Wiegell","year":"2006","unstructured":"Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol. 2006;154(5):969\u201376. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.07107.x.","journal-title":"Br J Dermatol"},{"key":"731_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/CCID.S35334","volume":"7","author":"MT Wan","year":"2014","unstructured":"Wan MT, Lin JY. Current evidence and applications of photodynamic therapy in dermatology. Clin Cosmet Investig Dermatol. 2014;7:145\u201363. https:\/\/doi.org\/10.2147\/CCID.S35334.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"731_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003412.pub3","volume":"11","author":"J Thomson","year":"2020","unstructured":"Thomson J, Hogan S, Leonardi-Bee J, Williams HC, Bath-Hextall FJ. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020;11: CD003412. https:\/\/doi.org\/10.1002\/14651858.CD003412.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"731_CR61","first-page":"50","volume":"6","author":"C Matei","year":"2013","unstructured":"Matei C, Tampa M, Poteca T, Panea-Paunica G, Georgescu SR, Ion RM, et al. Photodynamic therapy in the treatment of basal cell carcinoma. J Med Life. 2013;6(1):50\u20134.","journal-title":"J Med Life"},{"issue":"7","key":"731_CR62","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/archderm.134.7.821","volume":"134","author":"R Fink-Puches","year":"1998","unstructured":"Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol. 1998;134(7):821\u20136. https:\/\/doi.org\/10.1001\/archderm.134.7.821.","journal-title":"Arch Dermatol"},{"issue":"10","key":"731_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers8100090","volume":"8","author":"D Cohen","year":"2016","unstructured":"Cohen D, Lee P. Photodynamic therapy for non-melanoma skin cancers. Cancers. 2016;8(10):90. https:\/\/doi.org\/10.3390\/cancers8100090.","journal-title":"Cancers"},{"issue":"10","key":"731_CR64","doi-asserted-by":"publisher","first-page":"23300","DOI":"10.3390\/ijms161023300","volume":"16","author":"P Savoia","year":"2015","unstructured":"Savoia P, Deboli T, Previgliano A, Broganelli P. Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma. Int J Mol Sci. 2015;16(10):23300\u201317. https:\/\/doi.org\/10.3390\/ijms161023300.","journal-title":"Int J Mol Sci"},{"key":"731_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.9.1131","author":"LE Rhodes","year":"2007","unstructured":"Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007. https:\/\/doi.org\/10.1001\/archderm.143.9.1131.","journal-title":"Arch Dermatol"},{"issue":"3","key":"731_CR66","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.1994.112","volume":"69","author":"F Cairnduff","year":"1994","unstructured":"Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer. 1994;69(3):605\u20138. https:\/\/doi.org\/10.1038\/bjc.1994.112.","journal-title":"Br J Cancer"},{"issue":"8","key":"731_CR67","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/jdv.14164","volume":"31","author":"O Zaar","year":"2017","unstructured":"Zaar O, Fougelberg J, Hermansson A, Gillstedt M, Wennberg-Lark\u00f6 AM, Paoli J. Effectiveness of photodynamic therapy in Bowen\u2019s disease: a retrospective observational study in 423 lesions. J Eur Acad Dermatol Venereol. 2017;31(8):1289\u201394. https:\/\/doi.org\/10.1111\/jdv.14164.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"731_CR68","unstructured":"Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma\u2014PubMed. https:\/\/pubmed-ncbi-nlm-nih-gov.evms.idm.oclc.org\/17875873\/. Accessed 9 Aug 2021."},{"issue":"6","key":"731_CR69","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamadermatol.2015.5979","volume":"152","author":"HC Wulf","year":"2016","unstructured":"Wulf HC. Photodynamic therapy in daylight for actinic keratoses. JAMA Dermatol. 2016;152(6):631\u20132. https:\/\/doi.org\/10.1001\/jamadermatol.2015.5979.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"731_CR70","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/bjd.13138","volume":"171","author":"DM Rubel","year":"2014","unstructured":"Rubel DM, Spelman L, Murrell DF, See JA, Hewitt D, Foley P, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171(5):1164\u201371. https:\/\/doi.org\/10.1111\/bjd.13138.","journal-title":"Br J Dermatol"},{"issue":"4","key":"731_CR71","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jdv.14613","volume":"32","author":"E Sotiriou","year":"2018","unstructured":"Sotiriou E, Evangelou G, Papadavid E, Apalla Z, Vrani F, Vakirlis E, et al. Conventional vs daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12-month follow-up results of a randomized, intra-individual comparative analysis. J Eur Acad Dermatol Venereol JEADV. 2018;32(4):595\u2013600. https:\/\/doi.org\/10.1111\/jdv.14613.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"2","key":"731_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/jdv.12076","volume":"28","author":"SR Wiegell","year":"2014","unstructured":"Wiegell SR, Sk\u00f8dt V, Wulf HC. Daylight-mediated photodynamic therapy of basal cell carcinomas\u2014an explorative study. J Eur Acad Dermatol Venereol JEADV. 2014;28(2):169\u201375. https:\/\/doi.org\/10.1111\/jdv.12076.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"1","key":"731_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bjd.15364","volume":"177","author":"SM Gilbert","year":"2017","unstructured":"Gilbert SM, Gidley Baird A, Glazer S, Barden JA, Glazer A, Teh LC, et al. A phase I clinical trial demonstrates that nfP2X 7-targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol. 2017;177(1):117\u201324. https:\/\/doi.org\/10.1111\/bjd.15364.","journal-title":"Br J Dermatol"},{"issue":"4","key":"731_CR74","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"J Kim","year":"2010","unstructured":"Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388\u201399. https:\/\/doi.org\/10.1016\/j.ccr.2010.02.027.","journal-title":"Cancer Cell"},{"issue":"8","key":"731_CR75","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","volume":"32","author":"DJ Kim","year":"2014","unstructured":"Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):745\u201351. https:\/\/doi.org\/10.1200\/JCO.2013.49.9525.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"4","key":"731_CR76","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jamadermatol.2015.5473","volume":"152","author":"MS Ally","year":"2016","unstructured":"Ally MS, Ransohoff K, Sarin K, Atwood SX, Rezaee M, Bailey-Healy I, et al. Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatol. 2016;152(4):452\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2015.5473.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"731_CR77","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.3390\/cells8020153","volume":"8","author":"D Girardi","year":"2019","unstructured":"Girardi D, Barrichello A, Fernandes G, Pereira A. Targeting the hedgehog pathway in cancer: current evidence and future perspectives. Cells. 2019;8(2):E153. https:\/\/doi.org\/10.3390\/cells8020153.","journal-title":"Cells"},{"key":"731_CR78","unstructured":"PellePharm, Inc. Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients. clinicaltrials.gov; 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02762084. Accessed 15 Jun 2022."},{"key":"731_CR79","unstructured":"PellePharm, Inc. A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome). clinicaltrials.gov; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04308395. Accessed 15 Nov 2021."},{"issue":"25","key":"731_CR80","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2017.76.6691","volume":"36","author":"J Dantal","year":"2018","unstructured":"Dantal J, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results. J Clin Oncol. 2018;36(25):2612\u201320. https:\/\/doi.org\/10.1200\/JCO.2017.76.6691.","journal-title":"J Clin Oncol"},{"issue":"4p2","key":"731_CR81","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1524-4725.2004.30148.x","volume":"30","author":"S Euvrard","year":"2004","unstructured":"Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg. 2004;30(4p2):628\u201333. https:\/\/doi.org\/10.1111\/j.1524-4725.2004.30148.x.","journal-title":"Dermatol Surg"},{"key":"731_CR82","unstructured":"Palvella Therapeutics, Inc. A Multicenter, Phase 2B, Randomized, Double-Blind, Stratified, Vehicle-Controlled Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel In Prevention Of BCCs In Patients With Gorlin Syndrome. clinicaltrials.gov; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04893486. Accessed 24 Feb 2022"},{"key":"731_CR83","unstructured":"Berg, LLC. Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma. clinicaltrials.gov; 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00604890. Accessed 14 Oct 2021."},{"issue":"7","key":"731_CR84","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","volume":"14","author":"AHMM Arits","year":"2013","unstructured":"Arits AHMM, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJM, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(13)70143-8.","journal-title":"Lancet Oncol"},{"issue":"8","key":"731_CR85","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jid.2016.03.043","volume":"136","author":"MH Roozeboom","year":"2016","unstructured":"Roozeboom MH, Arits AHMM, Mosterd K, Sommer A, Essers BAB, de Rooij MJM, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136(8):1568\u201374. https:\/\/doi.org\/10.1016\/j.jid.2016.03.043.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"731_CR86","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jid.2017.09.033","volume":"138","author":"MHE Jansen","year":"2018","unstructured":"Jansen MHE, Mosterd K, Arits AHMM, Roozeboom MH, Sommer A, Essers BAB, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018;138(3):527\u201333. https:\/\/doi.org\/10.1016\/j.jid.2017.09.033.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"731_CR87","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/archderm.143.9.1131","volume":"143","author":"LE Rhodes","year":"2007","unstructured":"Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131\u20136. https:\/\/doi.org\/10.1001\/archderm.143.9.1131.","journal-title":"Arch Dermatol"},{"issue":"4","key":"731_CR88","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1684\/ejd.2015.2570","volume":"25","author":"C Morton","year":"2015","unstructured":"Morton C, Szeimies RM, Sidoroff A, Wennberg AM, Basset-Seguin N, Calzavara-Pinton P, et al. European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol EJD. 2015;25(4):296\u2013311. https:\/\/doi.org\/10.1684\/ejd.2015.2570.","journal-title":"Eur J Dermatol EJD."},{"key":"731_CR89","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6153","volume":"347","author":"L Lansbury","year":"2013","unstructured":"Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347: f6153. https:\/\/doi.org\/10.1136\/bmj.f6153.","journal-title":"BMJ"},{"issue":"4","key":"731_CR90","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1524-4725.2007.33089.x","volume":"33","author":"T Rosen","year":"2007","unstructured":"Rosen T, Harting M, Gibson M. Treatment of Bowen\u2019s disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2007;33(4):427\u201331. https:\/\/doi.org\/10.1111\/j.1524-4725.2007.33089.x (discussion 431\u2013432).","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg Al."},{"issue":"3","key":"731_CR91","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1067\/mjd.2001.111335","volume":"44","author":"A Mackenzie-Wood","year":"2001","unstructured":"Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen\u2019s disease. J Am Acad Dermatol. 2001;44(3):462\u201370. https:\/\/doi.org\/10.1067\/mjd.2001.111335.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"731_CR92","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10227-002-0158-6","volume":"7","author":"H Bargman","year":"2003","unstructured":"Bargman H, Hochman J. Topical treatment of Bowen\u2019s disease with 5-Fluorouracil. J Cutan Med Surg. 2003;7(2):101\u20135. https:\/\/doi.org\/10.1007\/s10227-002-0158-6.","journal-title":"J Cutan Med Surg"},{"key":"731_CR93","unstructured":"Morton C, Horn M, Leman J, Tack B, B\u00e9dane C, Tjioe M, et al. A placebo controlled European study comparing MAL-PDT with cryotherapy and 5-fluoracil in patients with Bowen\u2019s disease: P09. 89. J Eur Acad Dermatol Venereol. 2004;18."},{"key":"731_CR94","unstructured":"Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)\u2014UpToDate. https:\/\/www-uptodate-com.evms.idm.oclc.org\/contents\/treatment-and-prognosis-of-low-risk-cutaneous-squamous-cell-carcinoma-cscc?search=Treatment%20and%20prognosis%20of%20low-risk%20cutaneous%20squamous%20cell%20carcinoma%20(cSCC)&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed 26 Dec 2021."},{"issue":"10","key":"731_CR95","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archdermatol.2011.260","volume":"147","author":"L Ly","year":"2011","unstructured":"Ly L, Kelly JW, O\u2019Keefe R, Sutton T, Dowling JP, Swain S, et al. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients. Arch Dermatol. 2011;147(10):1191\u20135. https:\/\/doi.org\/10.1001\/archdermatol.2011.260.","journal-title":"Arch Dermatol"},{"issue":"1","key":"731_CR96","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2340\/00015555-1861","volume":"95","author":"G Kirtschig","year":"2015","unstructured":"Kirtschig G, van Meurs T, van Doorn R. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate. Acta Derm Venereol. 2015;95(1):83\u20135. https:\/\/doi.org\/10.2340\/00015555-1861.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"731_CR97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/120347541201600405","volume":"16","author":"JG Wong","year":"2012","unstructured":"Wong JG, Toole JWP, Demers AA, Musto G, Wiseman MC. Topical 5% imiquimod in the treatment of lentigo maligna. J Cutan Med Surg. 2012;16(4):245\u20139. https:\/\/doi.org\/10.1177\/120347541201600405.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"731_CR98","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jdv.13252","volume":"30","author":"T Read","year":"2016","unstructured":"Read T, Noonan C, David M, Wagels M, Foote M, Schaider H, et al. A systematic review of non-surgical treatments for lentigo maligna. J Eur Acad Dermatol Venereol JEADV. 2016;30(5):748\u201353. https:\/\/doi.org\/10.1111\/jdv.13252.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"6","key":"731_CR99","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaad.2015.02.008","volume":"72","author":"SM Swetter","year":"2015","unstructured":"Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. J Am Acad Dermatol. 2015;72(6):1047\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.008.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"731_CR100","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2015.05.022","volume":"73","author":"AN Mora","year":"2015","unstructured":"Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol. 2015;73(2):205\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.022.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"731_CR101","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/jdv.14085","volume":"31","author":"D Tio","year":"2017","unstructured":"Tio D, van der Woude J, Prinsen CAC, Jansma EP, Hoekzema R, van Montfrans C. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol JEADV. 2017;31(4):616\u201324. https:\/\/doi.org\/10.1111\/jdv.14085.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"5","key":"731_CR102","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1365-2133.2009.09032.x","volume":"160","author":"AM Powell","year":"2009","unstructured":"Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009;160(5):994\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09032.x.","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00731-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T13:11:57Z","timestamp":1675343517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00731-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00731-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"12 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors YAA, AJ, and\u00a0ER declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.\u00a0VAP declares he has received honoraria for advisory boards from\u00a0Almirall, Inc., and\u00a0PhD Biosciences.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"YAA assisted with writing the manuscript and created Table . AJ assisted with writing the manuscript. ER assisted with writing the manuscript. VAP assisted with writing the manuscript. All authors reviewed the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}